Argonautica Private Wealth Management Inc. Has $350,000 Stake in Novartis AG (NYSE:NVS)

Argonautica Private Wealth Management Inc. increased its stake in Novartis AG (NYSE:NVS) by 8.3% in the 4th quarter, HoldingsChannel.com reports. The fund owned 3,596 shares of the company’s stock after purchasing an additional 277 shares during the quarter. Argonautica Private Wealth Management Inc.’s holdings in Novartis were worth $350,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the stock. Centaurus Financial Inc. increased its stake in Novartis by 1.7% in the third quarter. Centaurus Financial Inc. now owns 5,728 shares of the company’s stock valued at $659,000 after purchasing an additional 98 shares in the last quarter. Allen Wealth Management LLC increased its position in Novartis by 1.8% in the 3rd quarter. Allen Wealth Management LLC now owns 5,788 shares of the company’s stock valued at $666,000 after buying an additional 100 shares in the last quarter. WealthPlan Investment Management LLC increased its position in Novartis by 1.1% in the 3rd quarter. WealthPlan Investment Management LLC now owns 9,494 shares of the company’s stock valued at $1,092,000 after buying an additional 100 shares in the last quarter. Rothschild Investment LLC raised its stake in Novartis by 0.6% during the 4th quarter. Rothschild Investment LLC now owns 16,682 shares of the company’s stock worth $1,623,000 after buying an additional 101 shares during the period. Finally, Avidian Wealth Enterprises LLC boosted its holdings in Novartis by 1.3% in the third quarter. Avidian Wealth Enterprises LLC now owns 7,913 shares of the company’s stock worth $910,000 after acquiring an additional 102 shares in the last quarter. Institutional investors and hedge funds own 13.12% of the company’s stock.

Wall Street Analyst Weigh In

NVS has been the subject of several recent research reports. Morgan Stanley started coverage on Novartis in a report on Wednesday, February 12th. They set an “underweight” rating for the company. HSBC lowered shares of Novartis from a “hold” rating to a “reduce” rating in a research note on Wednesday, December 4th. Erste Group Bank reaffirmed a “hold” rating on shares of Novartis in a research note on Tuesday, November 19th. BMO Capital Markets lifted their price objective on shares of Novartis from $118.00 to $120.00 and gave the company a “market perform” rating in a report on Wednesday, October 30th. Finally, StockNews.com upgraded shares of Novartis from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 8th. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Novartis presently has a consensus rating of “Hold” and an average price target of $123.38.

Novartis Stock Up 0.5 %

NVS opened at $109.73 on Wednesday. Novartis AG has a fifty-two week low of $92.35 and a fifty-two week high of $120.92. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.04 and a quick ratio of 0.84. The company’s 50-day moving average is $101.90 and its 200 day moving average is $108.08. The firm has a market capitalization of $224.28 billion, a P/E ratio of 18.66, a PEG ratio of 1.70 and a beta of 0.58.

Novartis (NYSE:NVS) last released its earnings results on Friday, January 31st. The company reported $1.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.80 by $0.18. Novartis had a return on equity of 37.24% and a net margin of 23.56%. Research analysts expect that Novartis AG will post 8.45 earnings per share for the current fiscal year.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.